



Date: January 8, 2025

BSE Limited

P J Towers,
Dalal Street,
Mumbai – 400 001

National Stock Exchange of India Limited

Exchange Plaza, C-1, Block G,
Bandra Kurla Complex,
Bandra (E), Mumbai – 400 051

Script Code: 543904

Symbol: MANKIND

Dear Sir/ Madam,

Subject: Outcome of the Board Meeting held today i.e. January 8, 2025

Ref.: Regulation 30 the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”).

The Board of Directors of the Company at its meeting held today i.e. January 8, 2025, has *inter-alia*, considered, noted and approved the following matters:

1. resignation of Mr. Ashish Mittal from the position of Company Secretary and Compliance Officer of the Company w.e.f. the close of business hours on January 8, 2025, as part of internal re-structuring. Mr. Mittal will continue to work with the Company at his earlier position i.e. Assistant General Manager- Secretarial;
2. appointment of Mr. Hitesh Kumar Jain (ICSI Membership No. F6241) as Company Secretary and Compliance officer of the Company and Key Managerial Personnel w.e.f. January 9, 2025, as recommended by Nomination and Remuneration Committee;
3. the following Key Managerial Personnel of the Company are severally authorized for the purpose of dissemination of material event/information to the Stock Exchanges:

Sr. No.	Name and Designation	Contact Details
1	Mr. Ashutosh Dhawan Chief Financial Officer	Mankind Pharma Limited Corporate Office: 262, Okhla Industrial Estate, Phase – III, New Delhi 110020 Phone: 011 – 4684 6700 Email ID: investors@mankindpharma.com
2	Mr. Hitesh Jain Company Secretary & Compliance Officer	

4. Mr. Prakash Agarwal, President – Strategy has been designated as Senior Management Personnel (“SMP”) of the Company.

MANKIND PHARMA LIMITED



The detailed disclosure as required under SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 for point no. 1, 2 and 4 are enclosed as Annexure I respectively.

The meeting of Board of Directors of the Company commenced at 03:30 p.m. (IST) and concluded at 04:05 p.m. (IST).

You are requested to kindly take the above information on your records.

Thanking You,

Yours Faithfully,

For **Mankind Pharma Limited**

Ashutosh Dhawan
Chief Financial Officer

Encl.: As above

Disclosure as per SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015

Sr. No.	Particulars	Mr. Ashish Mittal	Mr. Hitesh Jain	Mr. Prakash Agarwal
1.	Reason for change viz. appointment, re-appointment, resignation, removal, death or otherwise;	Mr. Ashish Mittal resigned from the position of Company Secretary and Compliance Officer of the Company w.e.f. close of business hours on January 8, 2025	Mr. Hitesh Jain (ICSI Membership No. F6241) appointed as Company Secretary and Compliance officer of the Company and Key Managerial Personnel w.e.f. January 9, 2025	Based upon the recommendation of Nomination and Remuneration Committee, considering the responsibilities and profile of Mr. Prakash Agarwal, President – Strategy, the Board of Directors of the Company included him in the list of Senior Management Personnel (“SMP”) of the Company w.e.f. January 8, 2025
2.	Date of appointment/re-appointment/cessation (as applicable) & term of appointment/re-appointment;			
3.	Brief profile (in case of appointment);	Not Applicable	<p>Mr. Hitesh Kumar Jain, a qualified Company Secretary (a fellow member of the Institute of Company Secretaries of India) and a law graduate from Delhi University, is having over 21years of rich and insightful experience in Company Secretarial, Compliance, Corporate Governance and Legal functions. His expertise includes mergers, demergers, restructuring, raising funds through IPO, Rights Issue, QIPs etc.</p> <p>Prior to joining the Company, Mr. Hitesh was associated with Orient Electric Limited, a C K Birla group company, as Company Secretary & Compliance Officer, MPS Limited as GM Legal and Company Secretary, TV18 Broadcast Limited, a Network18 group company, as Company Secretary and Compliance Officer and Shyam Telecom Limited.</p>	<p>Mr. Prakash Agarwal joined Mankind Pharma on 29th August 2023 as President – Strategy leading growth initiatives, M&A and overseeing Investor relations. Prior to joining Mankind, Mr. Prakash was Executive Director (Pharma) and Deputy Head of Research at Axis Capital.</p> <p>Mr. Prakash has more than 20 years’ experience in capital markets covering Pharma and Healthcare sector across firms like JP Morgan, Deutsche Equities, RBS, CIMB and Axis Capital. Mr. Prakash has been awarded by Thomson Reuters several times for his research work in Pharmaceutical sector.</p> <p>Mr. Prakash is B. Com (Hons) from St. Xavier’s College, Kolkata and MBA from Institute of Management Technology (IMT), Ghaziabad.</p>

MANKIND PHARMA LIMITED



4.	Disclosure of relationships between directors (in case of appointment of a director).	Not Applicable	Not Applicable	Not Applicable
----	---	----------------	----------------	----------------

January 8, 2025

Board of Directors,
Mankind Pharma Limited,
262, Okhla Industrial Estate,
Phase-III, New Delhi-110020

Dear Sir/Ma'am,

Sub: Resignation from the position of Company Secretary and Compliance Officer of Mankind Pharma Limited ("Company")

I do hereby tender my resignation from the position of Company Secretary and Compliance Officer of the Company, effective from the closing of business hours on January 8, 2025, due to the ongoing organizational restructuring.

I would like to take this opportunity to express my sincere gratitude to the management, board members, and my colleagues for their support and trust during my tenure with the company. It has been a privilege to contribute to the company's growth, and I am grateful for the valuable experiences I have gained during my tenure as Company Secretary and Compliance Officer of the Company.

Kindly accept my resignation and take same on record.

Thanking You

Yours Faithfully,



Ashish Mittal